Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $28.85, but opened at $30.4199. Chugai Pharmaceutical shares last traded at $29.41, with a volume of 21,325 shares changing hands.

Analysts Set New Price Targets

Several research firms have issued reports on CHGCY. Smbc Nikko Sec. upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. UBS Group upgraded shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Trading Up 2.0%

The firm has a 50 day moving average of $29.12 and a two-hundred day moving average of $26.16. The stock has a market capitalization of $96.84 billion, a PE ratio of 33.82 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Thursday, January 29th. The company reported $0.25 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The company had revenue of $2.25 billion during the quarter. Equities research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.